Company Announcement no. 22/2013
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 20 November 2013
Warrant Programme - New Articles of Association
In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors of Veloxis Pharmaceuticals A/S has on 13 November 2013 issued 50,000 warrants for the subscription of nominally DKK 50,000 shares in the Company.
The amendment of the Articles of Association associated with the issue of warrants has today been registered with the Danish Business Authority. The new Articles of Association for Veloxis Pharmaceuticals A/S are attached.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Mobile: +1 917 647 9107 Mobile: +45 21 227 227
Email: wjp@veloxis.com Email: jst@veloxis.com
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is Envarsus® for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc.
Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
